



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

MAGE-B5 siRNA (m): sc-149222

BACKGROUND

The melanoma-associated antigen (MAGE) family consists of a number of antigens recognized by cytotoxic T lymphocytes. The MAGE genes were initially isolated from different kinds of tumors and, based on their virtually exclusive tumor-specific expression in adult tissues, they have been used as targets for cancer immunotherapy. MAGE genes encode for tumor-rejection antigens that are expressed in tumors of different histologic types and in normal testis and placenta. MAGE-B5 (melanoma-associated antigen B5), also known as CT3.3 (cancer/testis antigen 3.3), is a 275 amino acid protein that contains one MAGE domain and is expressed in testis. The gene encoding MAGE-B5 maps to human chromosome X, which consists of about 153 million base pairs and nearly 1,000 genes. Color blindness, hemophilia and Duchenne muscular dystrophy are well known X chromosome-linked conditions which affect males more frequently, as males carry a single X chromosome.

REFERENCES

1. Lucas, S., De Plaen, E. and Boon, T. 2000. MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression. *Int. J. Cancer* 87: 55-60.
2. Chomez, P., De Backer, O., Bertrand, M., De Plaen, E., Boon, T. and Lucas, S. 2001. An overview of the MAGE gene family with the identification of all human members of the family. *Cancer Res.* 61: 5544-5551.
3. Kirkin, A.F., Dzhandzhugazyan, K.N. and Zeuthen, J. 2002. Cancer/testis antigens: structural and immunobiological properties. *Cancer Invest.* 20: 222-236.
4. Deeb, S.S. 2005. The molecular basis of variation in human color vision. *Clin. Genet.* 67: 369-377.
5. Helderma-van den Enden, A.T., de Jong, R., den Dunnen, J.T., Houwing-Duistermaat, J.J., Kneppers, A.L., Ginjaar, H.B., Breuning, M.H. and Bakker, E. 2009. Recurrence risk due to germ line mosaicism: Duchenne and Becker muscular dystrophy. *Clin. Genet.* 75: 465-472.
6. Marcar, L., MacLaine, N.J., Hupp, T.R. and Meek, D.W. 2010. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. *Cancer Res.* 70: 10362-10370.
7. Sang, M., Wang, L., Ding, C., Zhou, X., Wang, B., Wang, L., Lian, Y. and Shan, B. 2011. Melanoma-associated antigen genes—an update. *Cancer Lett.* 302: 85-90.
8. Feng, Y., Gao, J. and Yang, M. 2011. When MAGE meets RING: insights into biological functions of MAGE proteins. *Protein Cell* 2: 7-12.

CHROMOSOMAL LOCATION

Genetic locus: Mageb5 (mouse) mapping to X C2.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

PRODUCT

MAGE-B5 siRNA (m) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see MAGE-B5 shRNA Plasmid (m): sc-149222-SH and MAGE-B5 shRNA (m) Lentiviral Particles: sc-149222-V as alternate gene silencing products.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

MAGE-B5 siRNA (m) is recommended for the inhibition of MAGE-B5 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor MAGE-B5 gene expression knockdown using RT-PCR Primer: MAGE-B5 (m)-PR: sc-149222-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.